OBIO — Orchestra BioMed Holdings, Inc.

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1814114 ·
Last close
$3.97
Market Cap
$237.73M
52W High
$4.89
52W Low
$3.70
ADV30
238,568
Next earnings
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral vascular disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 110,000 78,000 -22,076,000 -20,691,000 100,658,000 28,367,000 59,466,000
Dec 2025 30,917,000 30,866,000 6,754,000 6,245,000 114,857,000 34,690,000 61,287,000
Sep 2025 861,000 812,000 -20,313,000 -20,828,000 104,807,000 42,012,000 61,068,000
Jun 2025 836,000 790,000 -19,327,000 -19,363,000 42,825,000 18,749,000 42,530,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-48,963,000
Investing CF
$-26,941,000
Financing CF
$88,333,000
CapEx
$-489,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-1.80
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-362,579,000
Inventory
$310,000
Receivables
$95,000
ST Investments
$71,822,000
EBIT TTM
$-51,553,000
Pretax Income TTM
$-52,701,000
Interest Exp TTM
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$32,724,000
EBITDA
$-54,628,000
Free Cash Flow
$-25,953,624
Enterprise Value
$168,947,440
Total Cash
$94,400,000
Total Debt
$15,848,000
Shares Out
59,880,715
Trailing EPS
$-0.95
Book Value
$0.94
ROE
-161.1%
ROA
-43.0%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 33,482,000 -51,807,000 -52,701,000 114,857,000 61,287,000 -48,963,000
Dec 2024 2,638,000 -64,301,000 -61,024,000 76,173,000 43,215,000 -50,558,000
Dec 2023 2,760,000 -51,506,000 -49,120,000 95,212,000 27,169,000 -46,127,000
Dec 2022 3,533,000 -32,657,000 -33,608,000 95,572,000 43,038,000 -29,289,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-1.48

Peers — same industry

TickerNameMarket CapLastDaily %
PROF Profound Medical Corp. $246.01M $6.77
LUCD Lucid Diagnostics Inc. $211.74M $1.11
SMTI Sanara MedTech Inc. $210.13M $22.93
OSUR ORASURE TECHNOLOGIES INC $271.26M $3.94
SGHT Sight Sciences, Inc. $271.51M $4.99

News headlines (Yahoo Finance, 1h cache)

Favourable Signals For Orchestra BioMed Holdings: Numerous Insiders Acquired Stock
2026-05-21 11:10 · Yahoo
Orchestra BioMed to Participate in the Jefferies Global Healthcare Conference
2026-05-19 12:30 · Yahoo
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue Estimates
2026-05-12 21:40 · Yahoo
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
2026-05-12 20:18 · Yahoo
Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027
2026-05-12 12:30 · Yahoo
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
2026-05-07 23:05 · Yahoo
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
2026-05-06 12:25 · Yahoo
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
2026-05-06 12:01 · Yahoo
Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement
2026-05-06 12:00 · Yahoo
FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
2026-04-30 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.